UK’s NICE will cover $700K cost of GSK’s gene therapy; Evoke shares spike on NDA plans
→ The UK’s pharma price watchdog NICE has sanctioned coverage of GlaxoSmithKline’s gene therapy Strimvelis for “bubble baby” syndrome, which costs about $700,000 for the once-and-done therapy. About three babies a year are born with ADA-SCID in the UK every year, a condition characterized by a life-threatening case of immune deficiency that leaves children unprotected against lethal infections. NICE says this is the first OK where it used a different pricing guideline for extraordinarily rare diseases. The gene therapy is available in only one site in Italy, where UK patients will have to travel to for therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.